Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-CRC imaging-guided cetuximab optimization in metastatic colorectal cancer
NL-OMON50209Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab and panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Vrije University Medical Center. Started May 2014; status: active, not recruiting.
02
Drugs
cetuximabpanitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON50209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50209.